Floatz logo

Olaparib

Fallopian Tube Serous Adenocarcinoma

NRG OncologySmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Fallopian Tube Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Ohio State University Comprehensive Cancer Center
Phase 3BB
Adriamycin
National Cancer Institute (NCI)
Phase 2/3BB
Cediranib
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 39 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
hereditary breast ovarian cancer syndromeActive
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →